Goldman Sachs analyst Corinne Jenkins raised the firm’s price target on TG Therapeutics to $6 from $4 and reiterates a Sell rating on the shares. The approval of Briumvi came with a label largely in-line with expectations, Jenkins tells investors in a research note. The analyst raised her peak sales estimate to $660M from $570M but remains cautious on the near-term outlook for sales. The multiple sclerosis is dominated by Roche’s Ocrevus and key opinion leader checks indicate limited perceived differentiation between Briumvi and Ocrevus, Jenkins says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TGTX:
- Another Big Day for TGTX
- TG Therapeutics says about 6-9 months behind U.S. on potential EU approval
- TG Therapeutics says Briumvi annual maintenance WAC price $59,000
- TG says ‘ideally’ Briumvi to be in centers within 30-45 days of new year
- TG Therapeutics doesn’t see need to raise additional capital at this time